Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.5923 +0.0723 (+13.90%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,302,388
Open	0.5200
Bid (Size)	0.5600 (800)
Ask (Size)	0.5898 (100)
Prev. Close	0.5200
Today's Range	0.5082 - 0.5979
52wk Range	0.4300 - 5.140
Shares Outstanding	9,362,444
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Today 13:36 EST

From Schall Law

Via GlobeNewswire

VTGN INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026

Today 9:57 EST

From Faruqi & Faruqi LLP

Via GlobeNewswire

Performance

YTD	-12.8%	-12.8%
1 Month	-8.2%	-8.2%
3 Month	-86.8%	-86.8%
6 Month	-80.9%	-80.9%
1 Year	-79.8%	-79.8%

More News

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Today 8:54 EST

From Bernstein Liebhard LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

February 17, 2026

From Pomerantz LLP

Via GlobeNewswire

Vistagen Therapeutics Inc (NASDAQ:VTGN) Reports Mixed Q3 Results Amid Key Clinical Trial Updates ↗

February 12, 2026

Via Chartmill

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

February 17, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 16, 2026

From Schall Law

Via GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

February 14, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

February 14, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

VTGN Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Vistagen Therapeutics, Inc. Class Action

February 13, 2026

From Robbins LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 13, 2026

From Schall Law

Via GlobeNewswire

What's going on in today's pre-market session ↗

February 13, 2026

Via Chartmill

VistaGen (VTGN) Q3 2026 Earnings Call Transcript ↗

February 12, 2026

Via The Motley Fool

Which stocks are moving after the closing bell on Thursday? ↗

February 12, 2026

Via Chartmill

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

February 12, 2026

From Vistagen

Via Business Wire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

February 12, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

February 10, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 10, 2026

From Schall Law

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 06, 2026

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

February 05, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding The Upcoming Lead Plaintiff Deadline for the Filed Class Action Lawsuit

February 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

February 04, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

February 04, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

February 04, 2026

From Vistagen

Via Business Wire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 03, 2026

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?

Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?

Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?

The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market

What is the current price of Vistagen Therapeutics, Inc. - Common Stock?

The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.5923

When was Vistagen Therapeutics, Inc. - Common Stock last traded?

The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 02/19/26 04:00 PM ET

What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?

The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 5.55M

How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?

Vistagen Therapeutics, Inc. - Common Stock has 6M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.